Role of cytokine inhibition in chronic heart failure

November 09, 1999

Tumor Necrosis Factor Receptor Topic of Plenary, Oral Sessions

SEATTLE, November 2, 1999- Researchers continue to explore an emerging approach in the study of heart failure, a disease that affects nearly five million Americans and contributes to more than 260,000 deaths each year. New research on the effect of inhibiting the inflammatory cytokine tumor necrosis factor (TNF) will be presented at the 72nd Scientific Sessions of the American Heart Association (AHA) from November 7-11 in Atlanta.

"Inhibiting proinflammatory cytokines that may contribute to the progression of heart failure represents a unique and exciting approach for research in heart failure," said Douglas Mann, MD, professor of medicine at Baylor College of Medicine and a pioneer in this area of study. "Our initial studies with ENBRELÖ -- a soluble TNF receptor -- suggested that inhibiting TNF could improve the signs and symptoms of heart failure in patients with moderate heart failure, as well as improve some aspects of cardiac function in these patients."During the Scientific Sessions, three presentations will feature the role of TNF in chronic heart failure (CHF). Two of the oral sessions will present new data on the use of ENBREL (Etanercept) in CHF. The role of TNF also will be featured at Plenary Session VI on Tuesday morning. Following are details of the sessions.

Suppression of Cardioinflammatory Cytokines by ENBREL (Etanercept, p75 TNF Receptor Fusion Protein) Correlates with Clinical Improvement in Heart Failure Patients - Abstract # 107774
Sunday, November 7, 4:00 pm
Location: Room 365/367W
Presenter: Biykem Bozkurt, MD, Baylor College of Medicine

Plenary Session VII: Research in Heart Failure: Implications for Future Treatment
Presentation: Inflammatory Cytokines, Heart Failure, and Treatment
Tuesday, November 9, 10:55 am
Location: Ballroom
Presenter: Douglas L. Mann, MD, Baylor College of Medicine

Regression of Left Ventricular Remodeling in Chronic Heart Failure after Treatment with ENBREL (Etanercept, p75 TNF Receptor Fc Fusion Protein) - Abstract # 108069
Wednesday, November 10, 8:30 am
Location: Room 365/367W
Presenter: Biykem Bozkurt, MD, Baylor College of Medicine

Chronic heart failure occurs when the heart is damaged from heart attack, high blood pressure, or physical defect. While the heart continues to pump, it does so inefficiently, resulting in fluid retention and shortness of breath. Chronic heart failure often is a progressive disease and becomes irreversible, making heart transplant surgery the last alternative for keeping a patient alive. New treatments such as ENBREL are exploring ways to halt, or even reverse, the progression of heart failure.

Immunex Corporation

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to